Information For DPL XXXVI
The American Society for Pharmacy Law (ASPL) is an organization of attorneys, pharmacists, pharmacist-attorneys and students of pharmacy or law who are interested in the law as it applies to pharmacy, pharmacists, wholesalers, manufacturers, state and federal government and other interested parties.

ASPL is a non-profit which encourages diversity & inclusion with the Society, regardless of differing backgrounds, perspectives, experiences, orientations, origins, and practice settings. The Society embraces participation and diversity as it leads to advancing our purpose: 

  • Furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues;
  • Communicating accurate legal educational information; and
  • Providing educational opportunities for pharmacists, attorneys, and others who are interested in pharmacy law

Latest News

November 13, 2025

WH Announces Price Drop in GLP-1s, Other Drugs

The White House announced that it had reached agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk to reduce the prices Americans pay for GLP-1s and other drugs.

The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx. The price of Zepbound and Orforglipron, if approved, will fall from $1,086 per month to an average of $346 when purchased through TrumpRx. In the event that the FDA later approves the Wegovy pill, or certain similar “GLP-1” drugs in each company’s pipeline intended to be taken orally rather than as a shot, the initial dose of those drugs will be priced at $150 per month through TrumpRx.

The Medicare prices of Ozempic, Wegovy, Mounjaro, and Zepbound will be $245. State Medicaid programs will also have access to these medications at these prices. Medicare will be able to cover semaglutide and tirzepatide for patients with obesity and related comorbidities for the first time, and Medicare enrollees will pay a $50 monthly copay.

Additionally, the agreement provides for reduced costs on other Eli Lilly and Novo Nordisk medicines when purchased through TrumpRx. For example:

  • Eli Lilly will provide Emgality, a treatment for migraines, at $299 per pen, a discount of $443 off of the list price.
  • Eli Lilly will provide Trulicity, a commonly used diabetes medicine, at $389 per month, a discount of $598 off of the list price.
  • Novo Nordisk will provide widely used insulin products, including NovoLog and Tresiba, at $35 per month of supply.

The agreement also provides that Eli Lilly and Novo Nordisk will guarantee MFN prices on all new medicines that they bring to market, repatriate increased foreign revenue on existing products, and provide every State Medicaid program in the country access to MFN drug prices on their products.

[Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. White House 06 Nov 2025.]